Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to Post Q1 2025 Earnings of ($1.15) Per Share, HC Wainwright Forecasts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Enanta Pharmaceuticals in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will earn ($1.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.57) EPS and Q4 2025 earnings at ($1.66) EPS.

A number of other brokerages also recently commented on ENTA. JPMorgan Chase & Co. decreased their price objective on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, JMP Securities dropped their price objective on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Trading Up 1.3 %

Shares of ENTA opened at $12.93 on Thursday. The company’s fifty day simple moving average is $14.85 and its 200 day simple moving average is $12.09. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $28.25. The company has a market cap of $273.55 million, a price-to-earnings ratio of -2.07 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The company had revenue of $18.00 million during the quarter, compared to analyst estimates of $22.74 million.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ENTA. Nisa Investment Advisors LLC lifted its position in Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,281 shares during the last quarter. Clearstead Advisors LLC acquired a new stake in Enanta Pharmaceuticals during the 3rd quarter worth approximately $57,000. Quantbot Technologies LP boosted its stake in Enanta Pharmaceuticals by 2,300.0% in the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares during the period. Sherbrooke Park Advisers LLC acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at $113,000. Finally, State Board of Administration of Florida Retirement System bought a new position in Enanta Pharmaceuticals during the 1st quarter worth $118,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.